|
1
|
Use of normal tissue complication probability models in the clinic.
|
Int J Radiat Oncol Biol Phys
|
2010
|
4.33
|
|
2
|
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.
|
Radiother Oncol
|
2005
|
3.86
|
|
3
|
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
|
J Clin Oncol
|
2007
|
3.16
|
|
4
|
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
|
Lancet Oncol
|
2011
|
3.04
|
|
5
|
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?
|
Int J Radiat Oncol Biol Phys
|
2012
|
2.41
|
|
6
|
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
|
Int J Radiat Oncol Biol Phys
|
2007
|
2.21
|
|
7
|
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.
|
Radiother Oncol
|
2010
|
2.12
|
|
8
|
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response.
|
Radiother Oncol
|
2006
|
2.00
|
|
9
|
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.91
|
|
10
|
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
|
J Clin Oncol
|
2006
|
1.89
|
|
11
|
Integral radiation dose to normal structures with conformal external beam radiation.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.88
|
|
12
|
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
1.78
|
|
13
|
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.69
|
|
14
|
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.65
|
|
15
|
A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.59
|
|
16
|
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.44
|
|
17
|
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
|
J Clin Oncol
|
2010
|
1.40
|
|
18
|
A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.
|
Acta Oncol
|
2012
|
1.35
|
|
19
|
Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation.
|
Radiother Oncol
|
2002
|
1.29
|
|
20
|
Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.27
|
|
21
|
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.24
|
|
22
|
Molecular therapy in head and neck oncology.
|
Nat Rev Clin Oncol
|
2009
|
1.24
|
|
23
|
Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting.
|
Phys Med Biol
|
2008
|
1.23
|
|
24
|
Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.22
|
|
25
|
Biologic basis for combining drugs with radiation.
|
Semin Radiat Oncol
|
2006
|
1.20
|
|
26
|
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.18
|
|
27
|
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
|
Acta Oncol
|
2005
|
1.13
|
|
28
|
Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.10
|
|
29
|
Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study.
|
Phys Med Biol
|
2006
|
1.08
|
|
30
|
Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.08
|
|
31
|
Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.07
|
|
32
|
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review.
|
Radiother Oncol
|
2012
|
1.05
|
|
33
|
On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function.
|
Phys Med Biol
|
2009
|
1.04
|
|
34
|
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.04
|
|
35
|
Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based.
|
Radiother Oncol
|
2005
|
1.02
|
|
36
|
Radiogenomics: the search for genetic predictors of radiotherapy response.
|
Future Oncol
|
2014
|
1.01
|
|
37
|
Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study.
|
Radiother Oncol
|
2005
|
1.01
|
|
38
|
Reports of unexpected late side effects of accelerated partial breast irradiation--radiobiological considerations.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.00
|
|
39
|
Radiotherapy adapted to spatial and temporal variability in tumor hypoxia.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.99
|
|
40
|
Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.99
|
|
41
|
Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.
|
Neuro Oncol
|
2012
|
0.98
|
|
42
|
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience.
|
Head Neck
|
2010
|
0.98
|
|
43
|
An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.98
|
|
44
|
Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.
|
Nucl Med Biol
|
2011
|
0.97
|
|
45
|
Feasibility of dose painting using volumetric modulated arc optimization and delivery.
|
Acta Oncol
|
2010
|
0.96
|
|
46
|
Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.96
|
|
47
|
Influence of connective tissue diseases on the expression of radiation side effects: a systematic review.
|
Radiother Oncol
|
2006
|
0.95
|
|
48
|
Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.94
|
|
49
|
Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.93
|
|
50
|
Conducting radiogenomic research--do not forget careful consideration of the clinical data.
|
Radiother Oncol
|
2012
|
0.92
|
|
51
|
Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis.
|
Cancer
|
2011
|
0.91
|
|
52
|
Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.
|
Radiother Oncol
|
2012
|
0.91
|
|
53
|
Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale.
|
Cancer
|
2012
|
0.91
|
|
54
|
Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy.
|
Eur J Cancer
|
2006
|
0.90
|
|
55
|
Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary.
|
Radiother Oncol
|
2003
|
0.89
|
|
56
|
Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.89
|
|
57
|
Hypofractionated radiotherapy for breast cancer.
|
N Engl J Med
|
2010
|
0.87
|
|
58
|
Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study.
|
Radiother Oncol
|
2009
|
0.86
|
|
59
|
Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer.
|
Acta Oncol
|
2011
|
0.86
|
|
60
|
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.86
|
|
61
|
Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques.
|
Acta Oncol
|
2010
|
0.84
|
|
62
|
Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction.
|
Radiother Oncol
|
2013
|
0.84
|
|
63
|
Failure-probability driven dose painting.
|
Med Phys
|
2013
|
0.84
|
|
64
|
Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors.
|
Acta Oncol
|
2013
|
0.82
|
|
65
|
A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning.
|
Radiother Oncol
|
2006
|
0.82
|
|
66
|
Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.
|
Radiother Oncol
|
2012
|
0.81
|
|
67
|
Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
|
Clin Cancer Res
|
2004
|
0.81
|
|
68
|
Radiation oncology health technology assessment: the best is the enemy of the good.
|
Nat Clin Pract Oncol
|
2008
|
0.81
|
|
69
|
Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer.
|
Acta Oncol
|
2014
|
0.81
|
|
70
|
HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.81
|
|
71
|
Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.81
|
|
72
|
Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: minimizing the life years lost attributable to failure to control the disease and late complication risk.
|
Acta Oncol
|
2013
|
0.80
|
|
73
|
Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer.
|
Eur J Cancer
|
2004
|
0.79
|
|
74
|
Radiation dose response of normal lung assessed by Cone Beam CT - a potential tool for biologically adaptive radiation therapy.
|
Radiother Oncol
|
2011
|
0.78
|
|
75
|
Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.78
|
|
76
|
Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes.
|
Acta Oncol
|
2010
|
0.78
|
|
77
|
Linear accelerator radiosurgery for trigeminal neuralgia.
|
Neurosurgery
|
2005
|
0.78
|
|
78
|
Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.
|
Radiother Oncol
|
2004
|
0.77
|
|
79
|
Does a local bystander effect necessitate a revision of TCP models that are based on observed clinical data?
|
Acta Oncol
|
2006
|
0.77
|
|
80
|
Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery.
|
J Neurooncol
|
2013
|
0.77
|
|
81
|
Prescribing and evaluating target dose in dose-painting treatment plans.
|
Acta Oncol
|
2014
|
0.76
|
|
82
|
Locoregional recurrence following accelerated partial breast irradiation for early-stage invasive breast cancer: significance of estrogen receptor status and other pathological variables.
|
Ann Surg Oncol
|
2013
|
0.76
|
|
83
|
Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique.
|
Neuro Oncol
|
2013
|
0.76
|
|
84
|
Elevation of prostaglandin E2 in lung cancer patients with digital clubbing.
|
J Thorac Oncol
|
2012
|
0.76
|
|
85
|
Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!
|
J Clin Oncol
|
2005
|
0.76
|
|
86
|
Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.75
|
|
87
|
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer: in regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11-18).
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.75
|
|
88
|
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected men who have sex with men (MSM) in Nigeria.
|
AIDS
|
2017
|
0.75
|
|
89
|
In reply to Arcangeli et al.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.75
|
|
90
|
Time evolution of regional CT density changes in normal lung after IMRT for NSCLC.
|
Radiother Oncol
|
2013
|
0.75
|
|
91
|
Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.75
|
|
92
|
Corrigendum: Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse.
|
Sci Rep
|
2017
|
0.75
|
|
93
|
Late neurological complications after irradiation of malignant tumors of the testis.
|
Acta Oncol
|
2007
|
0.75
|